Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 13;11(4):140.
doi: 10.3390/diseases11040140.

Effectiveness and Safety of Fenofibrate in Routine Treatment of Patients with Hypertriglyceridemia and Metabolic Syndrome

Marat V Ezhov  1 , Gregory P Arutyunov  2
Affiliations

Effectiveness and Safety of Fenofibrate in Routine Treatment of Patients with Hypertriglyceridemia and Metabolic Syndrome

Marat V Ezhov et al. Diseases. .

Abstract

Background: Multiple trials have demonstrated the efficacy of fenofibrate for the management of dyslipidemia. Real-world evidence may provide important insights into the effectiveness and safety of fenofibrate in patients with metabolic syndrome and elevated triglyceride (TG) levels, but such evidence is currently scarce.

Materials and methods: A non-interventional study was conducted among routine healthcare providers. Patients with TG levels of >2.3 mmol/L on stable statin therapy starting fenofibrate treatment were enrolled. Data on medical history, fenofibrate treatment, change in lipid levels, and C-reactive protein (CRP) were collected from medical records every 3 months for 6 to 7 months of observation.

Results: Overall, 988 patients receiving fenofibrate were enrolled (median age [95% CI] 60 [26.0-86.0] years), and 46.4% of the participants were females. Most patients had concomitant cardiovascular disease. A baseline TG level of 3.6 ± 1.5 mmol/L was reduced by 50.1% to 1.7 ± 0.58 mmol/L at 6 months of treatment (p < 0.001). Baseline non-high-density lipoprotein cholesterol (non-HDL-C) levels decreased by 33.7% at 6 months. Total cholesterol and low-density lipoprotein levels by the end of follow-up were reduced by 24.7 and 25.5% (p < 0.001 for both). C-reactive protein level decreased more than 39% from baseline.

Conclusions: Fenofibrate in a real-world setting significantly reduced TG, LDL-C, and non-HDL-C levels. In addition, a C-reactive protein level reduction of 39% was achieved.

Keywords: C-reactive protein; fenofibrate; hypertriglyceridemia; non-HDL-cholesterol; triglyceride.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders of the study had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Figures

Figure 1
Figure 1
Patient flow chart.
Figure 2
Figure 2
Triglyceride level changes in overall cohort. Notes: The dots represent mean values and the error bars are standard deviations; †—p < 0.0001 compared to baseline.
Figure 3
Figure 3
Triglyceride level change in target subgroups. Notes: BMI—body mass index; T2DM—type 2 diabetes mellitus; the dots represent mean values, and the error bars are standard deviations. † p < 0.001 compared to Visit 1.
Figure 3
Figure 3
Triglyceride level change in target subgroups. Notes: BMI—body mass index; T2DM—type 2 diabetes mellitus; the dots represent mean values, and the error bars are standard deviations. † p < 0.001 compared to Visit 1.
Figure 4
Figure 4
Non-HDL cholesterol level changes in overall cohort. Notes: HDL—high-density lipoprotein; †—p < 0.0001 compared to baseline.
Figure 5
Figure 5
Other lipid profile parameters and C-reactive protein level changes. Notes: LDL-C—low-density lipoprotein cholesterol; HDL-C—high-density lipoprotein cholesterol; CRP—C-reactive protein; the dots represent mean value and the error bars are standard deviations; †—p < 0.001 compared to baseline.
See this image and copyright information in PMC

References

    1. Grundy S.M. Metabolic Syndrome Update. Trends Cardiovasc. Med. 2016;26:364–373. doi: 10.1016/j.tcm.2015.10.004. - DOI - PubMed
    1. O’Neill S., O’Driscoll L. Metabolic Syndrome: A Closer Look at the Growing Epidemic and Its Associated Pathologies. Obes. Rev. 2015;16:1–12. doi: 10.1111/obr.12229. - DOI - PubMed
    1. Alberti K.G., Zimmet P.Z. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus Provisional Report of a WHO Consultation. Diabet. Med. 1998;15:539–553. doi: 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S. - DOI - PubMed
    1. Saklayen M.G. The Global Epidemic of the Metabolic Syndrome. Curr. Hypertens. Rep. 2018;20:12. doi: 10.1007/s11906-018-0812-z. - DOI - PMC - PubMed
    1. Kassi E., Pervanidou P., Kaltsas G., Chrousos G. Metabolic Syndrome: Definitions and Controversies. BMC Med. 2011;9:48. doi: 10.1186/1741-7015-9-48. - DOI - PMC - PubMed